Parkside Investments LLC Has $1.16 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Parkside Investments LLC lessened its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 23.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 6,533 shares of the company’s stock after selling 1,967 shares during the quarter. Parkside Investments LLC’s holdings in Johnson & Johnson were worth $1,157,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Patron Partners LLC increased its holdings in shares of Johnson & Johnson by 12.7% during the first quarter. Patron Partners LLC now owns 6,625 shares of the company’s stock worth $1,174,000 after buying an additional 747 shares in the last quarter. Tandem Investment Advisors Inc. increased its holdings in shares of Johnson & Johnson by 4.8% in the first quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after purchasing an additional 15,003 shares in the last quarter. Argent Advisors Inc. increased its holdings in shares of Johnson & Johnson by 6.6% in the first quarter. Argent Advisors Inc. now owns 19,772 shares of the company’s stock valued at $3,504,000 after purchasing an additional 1,218 shares in the last quarter. Exeter Financial LLC increased its holdings in shares of Johnson & Johnson by 3.2% in the first quarter. Exeter Financial LLC now owns 26,431 shares of the company’s stock valued at $4,684,000 after purchasing an additional 819 shares in the last quarter. Finally, Winthrop Advisory Group LLC increased its holdings in shares of Johnson & Johnson by 3.7% in the first quarter. Winthrop Advisory Group LLC now owns 9,090 shares of the company’s stock valued at $1,611,000 after purchasing an additional 325 shares in the last quarter. Institutional investors and hedge funds own 68.78% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

Shares of JNJ stock opened at $174.20 on Friday. The stock’s fifty day moving average price is $176.00 and its two-hundred day moving average price is $174.37. The company has a market cap of $458.39 billion, a PE ratio of 25.36, a P/E/G ratio of 3.28 and a beta of 0.63. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter last year, the business posted $2.48 EPS. Johnson & Johnson’s revenue for the quarter was up 3.0% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.59%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. Citigroup lowered their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Daiwa Capital Markets initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Finally, Raymond James boosted their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $189.89.

Insider Activity at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *